---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-278582"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-06-23T12:45:37+00:00"
generated_at: "2026-06-23T12:50:31.732288+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Sangamo Therapeutics files for Chapter 11 bankruptcy; enters stalking horse asset sales to Lilly and Astellas

## Summary
- Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.
- Entered stalking horse APA with Lilly for $50M to sell technology platforms including STAC-BBB, zinc finger, Modular Integrase, and prion program.
- Entered stalking horse APA with Astellas for $25M upfront plus up to $25M milestones for Fabry disease candidate isaralgagene civaparvovec.
- Obtained $30M DIP financing commitment from Northridge ATM, LLC to fund post-petition operations, subject to court approval.
- Board approved restructuring eliminating ~51 roles (~40% of workforce); expects $3-4M severance costs; retaining 77 employees.

## SEC filing metadata
- accession: 0001193125-26-278582
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-06-23T12:45:37+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 1.03, 2.03, 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/0001193125-26-278582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-278582
- JSON: https://secwatch.observer/filing/0001193125-26-278582.json
- Plain text: https://secwatch.observer/filing/0001193125-26-278582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.